Cancer is the leading cause of death in our pet dogs over 1 year of age. Unfortunately, the diagnosis in pets is usually made in the advanced stage, decreasing the effectiveness of treatment and resulting in a poor prognosis. Preventative cancer screening programs such as annual mammograms and colonoscopies do not exist for dogs. Early identification and treatment are key to maximizing the chance of a positive outcome and survival. Routine blood work database testing (chemistry screen, CBC, urinalysis) are important, but do not detect cancer.
We are very excited to announce that PetDx, a molecular diagnostics company, has invited DVH to participate in a lifetime clinical study titled CLASSIC (Cancer Lifetime Assessment Screening Study in Canines) featuring OncoK9. OncoK9 is a first-in-class multi-cancer detection (MCED) test. It utilizes the same cutting edge genomic sequencing technology that has revolutionized early cancer detection in human patients. Data suggests that this test can detect 30 types of cancer with a simple blood draw.
Screening tests will be free to eligible pets.
Who is eligible?
Patients are enrolled in the trial by their primary care doctor. Once enrolled, an exam and OncoK9 test is performed every 6 months. If the test is negative, the patient will return in 6 months for the next assessment. If the test is positive, the patient is referred to a BluePearl Oncology clinic for a diagnostic workup to attempt to identify the cancer. This is a funded collaborative effort between BluePearl, PetDx, and primary care doctors in the Greater Philadelphia area.
Cancer treatment is not included in the study.
If you are interested in participating in this study, please email email@example.com. If your pet meets the requirements, we will contact you to schedule an appointment to sign the consent forms, fill out a health questionnaire, and submit your pet’s blood sample. There are limited spaces available. As always, we are always happy to answer any questions you may have.